James Mock
Summary
James Mock is Moderna’s Chief Financial Officer and has held the position since joining the company in September 2022. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817925000082/mrna-20250310.htm?utm_source=openai))
Biography
Mock holds a bachelor’s degree in economics from St. Lawrence University. Before joining Moderna, he was Senior Vice President and Chief Financial Officer of PerkinElmer from 2018 to 2022. Earlier in his career, he spent nearly two decades at General Electric in a variety of financial and operating roles, most recently as Vice President of the Corporate Audit Staff. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817925000082/mrna-20250310.htm?utm_source=openai)) At Moderna, Mock oversees accounting, financial planning and analysis, business development, treasury, real estate, investor relations, internal audit, and tax. His tenure has focused on managing the company’s transition from pandemic-era vaccine revenue to a smaller commercial base while preserving spending on its research pipeline. He has also been involved in cost reductions, financial systems upgrades, financing arrangements, and plans to reach cash breakeven. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817925000082/mrna-20250310.htm?utm_source=openai))
Notable achievements
- Led initiatives credited by Moderna with reducing cash operating costs by 27% in 2024 while maintaining investment in the pipeline. ([d18rn0p25nwr6d.cloudfront.net](https://d18rn0p25nwr6d.cloudfront.net/CIK-0001682852/7ce87d1c-d369-44b7-aff6-72afcdac829a.pdf?utm_source=openai))
- Oversaw implementation of Moderna’s new enterprise resource planning system to improve financial processes and scalability. ([d18rn0p25nwr6d.cloudfront.net](https://d18rn0p25nwr6d.cloudfront.net/CIK-0001682852/7ce87d1c-d369-44b7-aff6-72afcdac829a.pdf?utm_source=openai))
- Helped develop a multiyear cost-reduction plan that targeted more than $6 billion in annual GAAP expense reductions from 2023 through 2027. ([investors.modernatx.com](https://investors.modernatx.com/files/doc_financials/2025/q1/MRNA-USQ_Transcript_2025-05-01.pdf?utm_source=openai))
- Helped secure a five-year, non-dilutive $1.5 billion term loan facility in support of Moderna’s balance sheet and financing flexibility. ([modernatx.com](https://www.modernatx.com/en-US/media-center/all-media/blogs/moderna-2025-shareholder-letter?utm_source=openai))
Problem areas / controversies
- Moderna’s proxy statement said Mock faced challenges in revenue forecasting and demand planning during 2024. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817925000082/mrna-20250310.htm?utm_source=openai))
- The company reduced its 2025 revenue outlook as demand timing and commercial conditions weakened, adding pressure to the finance organization’s planning assumptions. ([apnews.com](https://apnews.com/article/f7564b5f3f7802e7943f8fe16bec0738?utm_source=openai))
- Moderna continued to report large operating losses and cash use while investing in research and development, making cost control and liquidity management central challenges for Mock’s tenure. ([modernatx.com](https://www.modernatx.com/en-US/media-center/all-media/blogs/moderna-2025-shareholder-letter?utm_source=openai))
- Moderna granted Mock a special equity award in 2024 after the company’s share price decline reduced the value of his existing compensation, a decision that may draw scrutiny from shareholders focused on pay and performance alignment. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1682852/000130817925000082/mrna-20250310.htm))